SAVE THE DATE (10 November 2010): What should the WIPO SCCR do about limitations & exceptions: the way forward?
On 10 November 2010, Knowledge Ecology International will hold a side event from 13:30 to 14:45 in the Uchtenhagen room at WIPO which shall address the question, “What should the WIPO SCCR do about limitations & exceptions: the way forward”? Speakers include representatives from the Centre for Internet & Society, Egypt, the International Publishers Association, KEI and the South Centre. This is an open event. Please see below for details.
What should the WIPO SCCR do about limitations & exceptions: the way forward?
Invitation to the KEI side bar event
Six recent secret ACTA documents
SCCR 21: General statement of Group B (covering broadcasting, AV protection and limitations and exceptions)
The following general statement was delivered by France, on behalf of Group B, on the first day (8 November 2010) of SCCR 21.
SCCR 21
Group B opening statementI thank you M. Chair,
Group B is glad to welcome you back in Geneva for this 21st session of the Standing Committee on Copyright and Related Rights, which we hope will be a productive one.
SCCR 21: Initial impressions from day 1
The 21st session of the WIPO Standing Committee on Copyright and Related Rights (SCCR) commenced its work at 10:33 AM on Monday, 8 November 2010.
This unusually quick start is perhaps indicative of Member States’ commitment to examine the three substantive agenda items up for consideration during this five day negotiation; these three issues include: 1) protection of broadcasting organizations, 2) protection of audiovisual performances and 3) limitations and exceptions.
1 Global Fund calls upon drug companies to “share without delay” AIDS drug patents with the Medicines Patent Pool
In a October 7, 2010 letter, Professor Michel Kazatchkine, the Executive Director of the Global Fund to fight AIDS, Tuberculosis and Malaria, has written to Dr. Jorge Bermudez, the UNITAID Executive Director, to discuss the Medicines Patent Pool.
Kazatchkine congratulates UNITAID for the announcement that an agreement had been reached between U.S. National Institute for Health and the Medicines Patent Pool for the voluntary license of the NIH patents rights on an HIV-AID drug, Darunavir.
European generic drug companies ask EU Parliament to remove patents from ACTA
The European Generics Association has written to the European Parliament asking that patents be removed from the Anti-Counterfeiting Agreement. A PDF copy of their letter is here. The text in html follows:
MEP Mr. Gianluca Susta
INTA Committee
European Parliament
1049 Bruxelles- BelgiumBrussels, 5th of November 2010
Ref. EGA comments to the consolidated text on ACTA that reflects changes made during the
September 2010 Tokyo round1.
Dear Mr. Susta,
1 ACTA: USTR’s talking points to WTO Council for TRIPS
The following statement is the oral intervention made by USTR at the WTO Council for TRIPS (October 2010) regarding ACTA.
Talking Points of the United States for TRIPS Council Meeting of October 26, 2010
Agenda Item P
ACTAWe would like to thank other delegations for their interest in the Anti-Counterfeiting Trade Agreement (ACTA).
Delegations will recall that the United States and other delegations have been interested in discussing the issue of IP enforcement at this Council for many years and so we’re pleased to have another discussion today.Statement of the United States to WTO TRIPS Council on the Paragraph 6 System
The following statement was delivered by USTR at the WTO Council for TRIPS Annual Review of the Paragraph 6 System on Wednesday, 27 October 2010.
Statement of the United States
Agenda item F, Annual Review of the Paragraph 6 System
Topic 5Mr. Chairman
We are pleased to be here today to participate in the annual review on the implementation of paragraph 6 of the Doha Declaration.
The 2010 US elections
This was originally published in the Huffington Post here.
————
Continue ReadingSenator Sanders Letter to FDA: U.S. needs an ethical pathway for biological products
On November 2, 2010, U.S. Senator Bernard Sanders (VT-I) sent a letter to Margaret Hamburg, the FDA Commissioner, urging the agency to review the ethical implications of the 12 years of marketing exclusivity created by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act).